Literature DB >> 6717540

Neurologic outcome in children with inborn errors of urea synthesis. Outcome of urea-cycle enzymopathies.

M Msall, M L Batshaw, R Suss, S W Brusilow, E D Mellits.   

Abstract

We studied 26 children with inborn errors of urea synthesis who survived neonatal hyperammonemic coma. There was a 92 per cent one-year survival rate associated with nitrogen-restriction therapy and stimulation of alternative pathways of waste nitrogen excretion. Seventy-nine per cent of the children had one or more developmental disabilities at 12 to 74 months of age; the mean IQ was 43 +/- 6. There was a significant negative linear correlation between duration of Stage III or IV neonatal hyperammonemic coma and IQ at 12 months (r = -0.72, P less than 0.001) but not between the peak ammonium level (351 to 1800 microM) and IQ. There was also a significant correlation between CT abnormalities and duration of hyperammonemic coma (r = 0.85, P less than 0.01) and between CT abnormalities and concurrent IQ (r = -0.75, P less than 0.02). These results suggest that prolonged neonatal hyperammonemic coma is associated with brain damage and impairment of intellectual function. This outcome may be prevented by early diagnosis and therapy.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6717540     DOI: 10.1056/NEJM198406073102304

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  100 in total

1.  Increased intracranial pressure in a neonate with citrullinaemia.

Authors:  J L Wayenberg; D Vermeylen; E Gerlo; A Pardou
Journal:  Eur J Pediatr       Date:  1992-02       Impact factor: 3.183

Review 2.  Ornithine carbamoyl transferase deficiency: findings, models and problems.

Authors:  C Bachmann
Journal:  J Inherit Metab Dis       Date:  1992       Impact factor: 4.982

3.  Long-term outcome and intervention of urea cycle disorders in Japan.

Authors:  Jun Kido; Kimitoshi Nakamura; Hiroshi Mitsubuchi; Toshihiro Ohura; Masaki Takayanagi; Masafumi Matsuo; Makoto Yoshino; Yosuke Shigematsu; Tohru Yorifuji; Mureo Kasahara; Reiko Horikawa; Fumio Endo
Journal:  J Inherit Metab Dis       Date:  2011-12-14       Impact factor: 4.982

4.  Acute extrapyramidal syndrome in mild ornithine transcarbamylase deficiency: metabolic stroke involving the caudate and putamen without metabolic decompensation.

Authors:  C E Keegan; D M Martin; D J Quint; J L Gorski
Journal:  Eur J Pediatr       Date:  2003-02-07       Impact factor: 3.183

5.  Specificity of PCR-SSCP for detection of the mutant ornithine transcarbamylase (OTC) gene in patients with OTC deficiency.

Authors:  R Hoshide; T Matsuura; S Komaki; E Koike; I Ueno; I Matsuda
Journal:  J Inherit Metab Dis       Date:  1993       Impact factor: 4.982

6.  1H MRS identifies symptomatic and asymptomatic subjects with partial ornithine transcarbamylase deficiency.

Authors:  A L Gropman; S T Fricke; R R Seltzer; A Hailu; A Adeyemo; A Sawyer; J van Meter; W D Gaillard; R McCarter; M Tuchman; M Batshaw
Journal:  Mol Genet Metab       Date:  2008-07-26       Impact factor: 4.797

7.  Prenatal monitoring of ornithine transcarbamoylase deficiency in two families by DNA analysis.

Authors:  T Matsuura; R Hoshide; M Fukushima; T Sakiyama; M Owada; I Matsuda
Journal:  J Inherit Metab Dis       Date:  1993       Impact factor: 4.982

8.  Phenotypic correction of ornithine transcarbamylase deficiency using low dose helper-dependent adenoviral vectors.

Authors:  Nicola Brunetti-Pierri; Christian Clarke; Viraj Mane; Donna J Palmer; Brendan Lanpher; Qin Sun; William O'Brien; Brendan Lee
Journal:  J Gene Med       Date:  2008-08       Impact factor: 4.565

Review 9.  The Role of RRT in Hyperammonemic Patients.

Authors:  Shruti Gupta; Andrew Z Fenves; Robert Hootkins
Journal:  Clin J Am Soc Nephrol       Date:  2016-05-19       Impact factor: 8.237

Review 10.  Patterns of brain injury in inborn errors of metabolism.

Authors:  Andrea L Gropman
Journal:  Semin Pediatr Neurol       Date:  2012-12       Impact factor: 1.636

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.